Equities Analysts Offer Predictions for argenx Q2 Earnings

argenx SE (NASDAQ:ARGX) – Investment analysts at Leerink Partnrs reduced their Q2 2025 earnings per share estimates for argenx in a report released on Friday, May 9th. Leerink Partnrs analyst T. Smith now anticipates that the company will earn $2.19 per share for the quarter, down from their prior estimate of $2.40. The consensus estimate for argenx’s current full-year earnings is $3.13 per share. Leerink Partnrs also issued estimates for argenx’s Q3 2025 earnings at $2.60 EPS and Q4 2025 earnings at $2.93 EPS.

argenx (NASDAQ:ARGX) last issued its quarterly earnings results on Thursday, May 8th. The company reported $2.58 EPS for the quarter, beating analysts’ consensus estimates of $2.32 by $0.26. The firm had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $748.34 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%.

ARGX has been the subject of a number of other research reports. Sanford C. Bernstein raised argenx from a “market perform” rating to an “outperform” rating in a report on Monday, March 17th. HC Wainwright restated a “buy” rating and set a $720.00 price objective on shares of argenx in a research note on Tuesday, April 8th. William Blair restated an “outperform” rating on shares of argenx in a research note on Friday, February 28th. Robert W. Baird upped their price objective on argenx from $650.00 to $680.00 and gave the company a “neutral” rating in a research note on Tuesday, March 4th. Finally, Wedbush restated an “outperform” rating and set a $715.00 price objective on shares of argenx in a research note on Friday, April 11th. Three investment analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, argenx currently has a consensus rating of “Moderate Buy” and a consensus price target of $697.94.

argenx Stock Performance

Shares of ARGX opened at $560.90 on Monday. The company has a market capitalization of $34.25 billion, a P/E ratio of -637.39 and a beta of 0.57. argenx has a one year low of $352.77 and a one year high of $678.21. The stock has a 50-day moving average price of $594.76 and a 200 day moving average price of $613.84.

Institutional Trading of argenx

Several large investors have recently added to or reduced their stakes in ARGX. FMR LLC increased its position in argenx by 17.2% in the 4th quarter. FMR LLC now owns 5,618,222 shares of the company’s stock valued at $3,455,207,000 after acquiring an additional 824,750 shares during the period. Point72 Asset Management L.P. acquired a new stake in argenx in the 4th quarter valued at approximately $91,013,000. Allspring Global Investments Holdings LLC increased its position in argenx by 38,152.3% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 144,211 shares of the company’s stock valued at $89,391,000 after acquiring an additional 143,834 shares during the period. GAMMA Investing LLC increased its position in argenx by 53,684.9% in the 1st quarter. GAMMA Investing LLC now owns 135,538 shares of the company’s stock valued at $802,200,000 after acquiring an additional 135,286 shares during the period. Finally, Marshall Wace LLP increased its position in argenx by 184.7% in the 4th quarter. Marshall Wace LLP now owns 191,553 shares of the company’s stock valued at $117,805,000 after acquiring an additional 124,271 shares during the period. 60.32% of the stock is currently owned by institutional investors and hedge funds.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.